(Adnkronos) - Otsuka, azienda farmaceutica giapponese di lunghissima tradizione (100 anni nel 2021), dal 1974 è presente anche nel Vecchio Continente. Oggi l'azienda conta nel mondo 34.388 dipendenti, un fatturato consolidato di circa 13,27 miliardi di euro e una spesa di 2 miliardi in Ricerca e Sviluppo nel 2023. In Europa impiega circa 500 dipendenti ed è focalizzata anche sullo sviluppo di terapie digitali.
Category
🗞
NewsTranscript
00:00From Japan to Europe to innovate and develop new therapies, especially in areas of psychiatry,
00:11neurology, infectious diseases, nephrology and oncology.
00:15This is Otsuka, who celebrates his first 50 years in Europe.
00:1950 years ago, Otsuka Pharmaceutical started its research and development activities in the area of CNS,
00:25that is, psychiatry and neurology.
00:27Fortunately, they have found important solutions that have become market leaders in the area of psychiatry,
00:34especially in psychosis.
00:36After that, in recent years, it has also developed all the research and development in the area of nephrology.
00:42More recently, a product with indication in the nephritic lupus has been launched
00:47and now in Italy we are introducing a new treatment for acute myeloid leukemia.
00:52But this is the present, we expect a lot for the future.
00:55We are entering new therapeutic areas, but all of them in rare diseases,
00:59especially in the accumulation nephropathy of immunoglobulin A, hereditary angioedema,
01:04phenylketonuria and, as announced last week, very recently,
01:09in SLA with genetic mutation FUR.
01:14The Japanese company, founded in 1921, has 34,388 employees worldwide.
01:21A consolidated turnover of about 13.7 billion euros
01:25and a spending of 2 billion in research and development in 2023.
01:29The commitment in the field of hematology is always important.
01:33The contribution of Otsuka in oncohematology is extremely important
01:38as it is developing new oral drugs
01:42that can be therapeutic alternatives for patients affected by acute myeloid leukemia.
01:50These patients have unmet medical needs,
01:54that is, extremely relevant unresolved clinical needs
01:58and this contribution of innovation will improve both the survival
02:04and the quality of life of patients affected by acute myeloid leukemia.
02:08In Europe it employs about 500 employees
02:11and is also focused on the development of digital therapies,
02:15maintaining its role as a leader in mental health.
02:18The contribution of Otsuka to the care and management
02:22of people affected by mental disorders
02:24has been truly decisive and, I would say, innovative.
02:29Initially, with the start of Otsuka's activity in the field of mental health,
02:35we had a completely new drug, ripiprazole,
02:39which was provided mainly for oral use,
02:42which allowed to manage a series of symptoms
02:45that with traditional drugs it was not possible to deal with,
02:49especially the negative symptoms of schizophrenia and the positive symptoms.